
News|Articles|May 1, 2002
Lercanidipine: A long-acting dihydropyridine calcium channel blocker for treatment of hypertension
Lercanidipine is currently under FDA review for the management of hypertension. In comparative clinical trials, lercanidipine has shown antihypertensive efficacy comparable to that of slow-release nifedipine, amlodipine, nitrendipine, verapamil, captopril, and atenolol. Its side effect profile is similar or superior to these agents. This Focus article reviews those trials as well as lercanidipine?s pharmacologic properties and addresses the agent?s potential role in patients with comorbid conditions.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Time for a 'new car smell' for managing cell and gene therapy costs
2
Takeaways about bispecific antibodies
3
Eli Lilly acquires three vaccine companies for infectious disease portfolio
4
Operational challenges for health systems and managing side effects
5



























